Bridget Flynn: An Opportunity to Support Medication Management for Stroke Survivors
Bridget Flynn, Director of Development, Principal and Major Gifts at Woods Hole Oceanographic Institution, shared Jonathan Rosand‘s post on LinkedIn:
”Sharing this opportunity that could make a meaningful difference for stroke survivors.
If you or someone you know has had a stroke in the past year, this fully remote study from Mass General Brigham and Harvard Medical School is focused on helping with medication management.
Details below.”
Jonathan Rosand, Founder of Global Brain Care, Director of Brain Care Labs at Mass General Brigham, shared on LinkedIn:
”Have you or a loved one had a stroke in the past year, and would you like help managing your medications?
The Savvy Study Team at Mass General Brigham and Harvard Medical School are now recruiting stroke survivors across the U.S. for a fully remote study to support you in taking your medications.
Please see the flyer below for more details.
Visit for more information and to express interest.
Get in touch at [email protected] if you have any questions.”

Stay updated with Hemostasis Today.
-
Sep 5, 2026, 16:28Jon Douglas: Imperial College London Review Maps Key Pathways in Autoimmune Thrombosis
-
Sep 5, 2026, 16:21Kelly Anderson: Bilateral Foot Pain and Purple Toes – Spotting Vascular Complications in Polycythemia Vera
-
Sep 5, 2026, 16:16Hazem Abosheaishaa: Beta-Blocker Selection Matters – Multi-Institutional Cohort Insights on PVT and Survival in Cirrhosis
-
Sep 5, 2026, 16:08Indre Ceponiene: Major Gaps in Secondary Cardiovascular Prevention Across Europe
-
Sep 5, 2026, 16:03W. Alberto Sifuentes Giraldo: Why Obstetric Cases Are Missed Under 2023 ACR/EULAR APS Criteria
-
Sep 5, 2026, 15:58Srikanth Nalla: A Case of Saddle Pulmonary Embolism
-
Sep 5, 2026, 15:55COPD-specific Pulmonary Embolism Diagnostic Strategy – Thrombosis and Haemostasis
-
Sep 5, 2026, 15:41Sam Tsimikas on Lp(a) HORIZON Topline Results – What Missed Endpoints Mean for Cardiovascular Risk
-
Sep 5, 2026, 15:32Stefano Garzon: SELUTION DeNovo HBR – Weren’t HBR Patients Supposed to Bleed More with DES?